2000 Sierra Point Parkway
Tercica, Inc., based in Brisbane, California, is a biopharmaceutical company committed to improving endocrine health. We are helping patients by partnering with the endocrine community to develop and commercialize new therapeutics for short stature, our initial market opportunity, and associated metabolic disorders.
Our flagship product is Increlex™ (mecasermin [rDNA origin] injection), or recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica licensed rights to develop, manufacture, and commercialize Increlex from Genentech, Inc. We are currently conducting a broad-scale Phase IIIb clinical study to evaluate the safety and efficacy of Increlex in children with Primary IGFD.
Beyond Increlex, Tercica intends to build a franchise of endocrinology products through our own internal development efforts and through strategic in-licensing.
Tercica was born out of technology and intellectual property from Genentech for recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Founded by noted scientists and clinicians in endocrinology and the field of growth hormone (GH) research, the company began operations in the United States in May, 2002 after licensing from Genentech exclusive rights to develop, commercialize, and manufacture rhIGF-1. Tercica also licensed Genentech rights to the rhIGF-1/IGFBP-3 binding protein complex, as well as to manufacturing processes, formulations, pre-clinical studies and clinical
studies associated with the rhIGF-1 program at Genentech.
The vision of Tercica's founders was to turn the promise of rhIGF-1 as a key mediator of growth and metabolism into a therapeutic reality for several diseases in need of new treatments. Leveraging an intensive multi-national research effort spanning nearly forty years and more than 20,000 publications which further establish IGF-1's central role in the endocrine system, Tercica was founded to bring rhIGF-1 back to its roots in growth biology and metabolism.
Tercica was founded by Professor Ross G. Clark of the University of Auckland; Professor Bengt-Åke Bengtsson, Professor of Endocrinology at Sahlgrenska University in Göteborg, Sweden; Professor Iain C.A.F. Robinson, head of Molecular Neuroendocrinology at the National Institute for Medical Research, Mill Hill, England, and Professor Olle G. P. Isaksson, head of the Department of Internal Medicine at Sahlgrenska University Hospital in Göteborg, Sweden, and by Mr. Howard Moore, our first executive. Professor Clark currently serves as our Chief Technical Officer. Professor Clark and Professor Isaksson serve as members of our Board of Directors.
Investor Relations: Fredrik Wiklund, Sr. Director, Corporate Development and Investor Relations